Mike Dixon joined Transformation Capital in 2019 after more than a decade of leading digital health growth equity efforts at Sequoia Capital.
Mike currently serves on the board of Health Catalyst (ticker: HCAT), Implantable Provider Group, and Clover Health. Previously, he served on the boards of Trialspark and Airstrip Technologies, among others. He also led or co-led additional healthcare investments in MedExpress (acquired by UnitedHealth Group), Stemcentrx (acquired by Abbvie), Cortexyme (ticker: CRTX), 23andMe, and BridgeBio (ticker: BBIO).
Prior to his time at Sequoia Capital, Mike was an Equity Research Associate at Fidelity Management & Research Company. He graduated summa cum laude from Boston College in 2006 and was a member of the Presidential Scholars Program.